Insights from IO & Biomarker Summit 2026: The Evolving Immuno-oncology Landscape
Published: March 24, 2026
The IO & Biomarker Summit brought together a diverse group of stakeholders across the oncology landscape to explore the latest advances in immuno-oncology and biomarker science.
We contributed to this year’s program through a capabilities presentation delivered by Karthikeyan Devaraju, Senior Scientist, R&D and Cell & Gene Therapy, highlighting integrated scientific approaches supporting immuno-oncology research across the development lifecycle.
Alongside this, the summit provided valuable perspectives from across the field, with discussions and presentations reflecting the rapid pace of innovation in areas such as cell and gene therapy, biomarker development, and AI-driven drug discovery.
Explore our key scientific insights, along with highlights from our presentation.
Insights from RSVVW 2026: Advancing the Future of RSV Research
Published: March 16, 2026
The 2026 ReSViNET RSVVW conference gathered more than 800 experts to discuss the rapidly evolving landscape of RSV therapeutics, vaccines, and surveillance. Our team contributed with a poster showcasing the strong analytical performance of our whole genome sequencing (WGS) assays for RSV research.
This year’s meeting highlighted major progress in antiviral development, including new molecules showing improved effectiveness later in infection and exploration of innovative delivery routes like spray-based therapies. Conversations also focused on vaccine strategies and the influence of public perception on uptake in a post‑COVID environment.
Our poster demonstrated the robustness and sensitivity of our RSV WGS assays, supporting their application in large-scale genomic surveillance and resistance monitoring in antiviral research.
Explore our full insights and details on our poster presentation in this blog.
Reach out to our experts and discover how we can help you transform your research and advance health
